Cyclosporin Prevents Diabetes in Bb Wistar Rats

Laupacis, Andreas; Gardell, C.; Dupré, J.; Stiller, C. R.; Keown, P. A.; Wallace, A. C.; Thibert, Pierre

doi:10.1016/s0140-6736(83)91558-1

Cited by 183 publications

(58 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cyclosporine, with its specific immunomQtfularory action (13)(14)(15) and TABLE 1 its efficacy and relat ive safety in comparison to other immu nosu ppressivc agents, particularly in organ t ransplantation ( 15,16), and its effective prevention of autoimmunity in an imal models ( 17,18), has prompted its experimental use in a series of autoimmu ne d isease:, in man ( 19), including Croh n 's disease. Preliminary stud ies with Crohn's disease have been encouraging (20)(21)(22).…”

Section: Rohn's D Isease Is a Chronicmentioning

confidence: 99%

Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy

Peltekian

Williams

Macdonald

et al. 1988

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

Fifteen pat ients with severe active Crohn's disease, refra ccory to conventional therapy, were given a 16 week cou rse of cyclosporine ar an initial oral daily dose of 10 mg/kg, adjusted to ma intain cyclosporine scrum trough levels between 100 and 200 ng/m l. Five patients withdrew early because of side effects, poor absorption or noncompliance. T he remaining 10 patients all improved within four weeks as measured by three d iffe rent clinical indices: Crohn's Disease Activity Index, Simple Index of Crohn's Disease A ctivity and Mean Score of Therapeutic Goals (MSTG). Seven patients maintained th is initial improvement and prcdnisone was either reduced or discontinued. Four of these seven patients relapsed with in four wceb of stopping cyclosporine, and three remain in remission after 75 ± 2 weeks. S ide effects were minor and easily reversible. When the various clinical and labo ratory indices were compared, MSTG was found to be the most useful index fo r the assessment of therapy. Cyclosporine appears to be a safe and effective therapy in patients with severe active Crohn's disease refractory to conventional therapy. Ca n J Gastroenterol 1988; 2(1): 5-11

show abstract

Section: Rohn's D Isease Is a Chronicmentioning

confidence: 99%

Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy

Peltekian

Williams

Macdonald

et al. 1988

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…2 The nonobese diabetic (NOD) mouse, derived from the CTS subline of an ICR strain, is an animal model of type I diabetes characterized by insulitis 9 and a perturbed immune system. 10^12 Ultrastructural examinations of female NOD mice show infiltration of macrophages and lymphocytes into the islets and reduction of islet size.…”

mentioning

confidence: 99%

Streptococcal Preparation (OK-432) Inhibits Development of Type I Diabetes in NOD Mice

et al. 1986

View full text Add to dashboard Cite

SUMMARYOK-432 (a streptococcal preparation) has been widely used for cancer immunotherapy in Japan. It is the most potent immunomodulator in activating both macrophages and killer T cells and in increasing interleukin 2 production. Two K.E. (Klinische Einheit, clinical unit) of OK-432 were given intraperitoneally to each of 17 female nonobese diabetic (NOD) mice every week from 4-24 wk of age. NOD mice as well as BB rats spontaneously develop type I diabetes. During administration of OK-432, the development of diabetes was inhibited in 17 of 17 mice over the 24-wk observation period, whereas 14 of 17 female NOD mice given physiological saline had developed diabetes by 24 wk of age. At the onset of diabetes, nonfasting blood glucose was 511 ± 8 2 mg/dl. Histologic examination showed that in the OK-432-treated NOD mice, 98% of total islets were intact or mildly infiltrated with mononuclear cells, whereas in saline-treated NOD mice, 79% of total islets exhibited severe insulitis. In OK-432-treated NOD mice, both the number of the mononuclear spleen cells and their natural killer cell activity was significantly increased. DIABETES 1986; 32:496-99. 10^12 Ultrastructural examinations of female NOD mice show infiltration of macrophages and lymphocytes into the islets and reduction of islet size. 13 As reported previously,

show abstract

“…The possibility by a number of techniques, to modulate or alter the immune response to decrease the incidence of diabetes in the spontaneously diabetic BB rat [45] have further stimulated efforts to carry out early immune intervention in man. Since cyclosporin A was found to decrease the incidence of diabetes in the BB rat [84], this drug was tested in an open study in man [85]. In this study some patients were not only able to discontinue their insulin therapy but their course of endogenous insulin production showed some increase compared with other patient populations.…”

Section: Future Studies: Possible Ways Of Preventing Diabetesmentioning

confidence: 99%

Molecular biology of Type 1 (insulin-dependent) diabetes mellitus

Lernmark¹

1985

Diabetologia

View full text Add to dashboard Cite

Cyclosporin Prevents Diabetes in Bb Wistar Rats

Cited by 183 publications

References 12 publications

Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy

Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy

Streptococcal Preparation (OK-432) Inhibits Development of Type I Diabetes in NOD Mice

Molecular biology of Type 1 (insulin-dependent) diabetes mellitus

Contact Info

Product

Resources

About